Adding serial circulating tumor DNA (ctDNA) assays to standard of care imaging surveillance had limited clinical benefits in ...

Pancreatic cancer screening has advanced significantly in recent years. There are now research-based guidelines on screening ...

A groundbreaking blood test for colorectal cancer screening could reshape early detection. Learn how this FDA-approved method ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

A new editorial was published in Oncotarget's Volume 15 on December 24, 2024, titled "Pitfalls and perils from FDA-approved germ-line cancer predisposition tests." ...

A groundbreaking study led by the Mayo Clinic Comprehensive Cancer Center has significantly deepened our understanding of ...

Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...

In a groundbreaking development, hundreds of newborns have started being tested for over 200 rare genetic conditions as part ...

"Inside Edition" correspondent Alison Hall opens up about her breast cancer battle and how Olivia Munn's own experience with early detection inspired her to take a life-saving risk assessment test.

With a focus on personalised medicine, AEON Clinic is redefining the way we approach health prevention and disease management ...